|
| 36454709 | Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). | Alzheimers Dement | 2023 |
| 37966285 | Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. | N Engl J Med | 2023 |
| 38055260 | Tominersen in Adults with Manifest Huntington's Disease. | N Engl J Med | 2023 |
| 37461624 | Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies <i>LRRC4C, LHX5-AS1</i> and nominates ancestry-specific loci <i>PTPRK</i> , <i>GRB14</i> , and <i>KIAA0825</i> as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium. | medRxiv | 2023 |
| 36641605 | Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. | J Prev Alzheimers Dis | 2023 |
| 34776434 | Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. | J Alzheimers Dis | 2022 |
| 35542994 | Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. | J Prev Alzheimers Dis | 2022 |
| 36447240 | Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. | Alzheimers Res Ther | 2022 |
| 35921451 | Trial of Prasinezumab in Early-Stage Parkinson's Disease. | N Engl J Med | 2022 |
| 36121669 | Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. | JAMA Neurol | 2022 |
| 33336218 | Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. | J Prev Alzheimers Dis | 2021 |
| 33569564 | Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. | J Prev Alzheimers Dis | 2021 |
| 33569561 | Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. | J Prev Alzheimers Dis | 2021 |
| 33579838 | Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. | J Alzheimers Dis | 2021 |
| 34585210 | Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. | J Prev Alzheimers Dis | 2021 |
| 34155411 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. | Nat Med | 2021 |
| 34101788 | Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. | J Prev Alzheimers Dis | 2021 |
| 32277473 | What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. | J Neurochem | 2020 |
| 32010919 | Viewpoint: The Role of Futility Analyses in Alzheimer's Disease Clinical Trials. | J Prev Alzheimers Dis | 2020 |
| 32573256 | Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. | Am J Alzheimers Dis Other Demen | 2020 |
| 31831056 | Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. | Alzheimers Res Ther | 2019 |
| 29741663 | Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. | J Gerontol B Psychol Sci Soc Sci | 2018 |
| 29972209 | What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. | J Prev Alzheimers Dis | 2018 |
| 28714976 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. | Nat Genet | 2017 |
| 28436391 | Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. | J Alzheimers Dis | 2017 |
| 28157100 | Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. | J Alzheimers Dis | 2017 |
| 28243501 | Validation of olfactory deficit as a biomarker of Alzheimer disease. | Neurol Clin Pract | 2017 |
| 29186281 | EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. | J Prev Alzheimers Dis | 2017 |
| 29181492 | Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech. | J Prev Alzheimers Dis | 2017 |
| 28550255 | Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). | J Alzheimers Dis | 2017 |
| 22421539 | Binomial regression with a misclassified covariate and outcome. | Stat Methods Med Res | 2016 |
| 28459045 | Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. | J Prev Alzheimers Dis | 2016 |
| 29210442 | Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. | J Prev Alzheimers Dis | 2016 |
| 26471212 | An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. | CNS Spectr | 2016 |
| 26444781 | Validation of the Spanish version of the Baylor Profound Mental Status Examination. | J Alzheimers Dis | 2016 |
| 27590297 | Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. | BMC Neurol | 2016 |
| 27172829 | Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. | Parkinsonism Relat Disord | 2016 |
| 27571265 | Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. | PLoS One | 2016 |
| 27276999 | PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. | BMC Neurol | 2016 |
| 26757777 | Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. | J Clin Exp Neuropsychol | 2016 |
| 26782946 | A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified. | Stat Med | 2016 |
| 26079412 | Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. | Alzheimers Dement | 2016 |
| 25938338 | Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. | Psychol Assess | 2015 |
| 29854931 | Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5Â years. | Alzheimers Dement (N Y) | 2015 |
| 28572692 | Joint coverage probability in a simulation study on Continuous-Time Markov Chain parameter estimation. | J Appl Stat | 2015 |
| 26247004 | Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. | J Prev Alzheimers Dis | 2015 |
| 26617181 | How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? | Clin Neuropsychol | 2015 |
| 27239525 | Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. | Alzheimers Dement (Amst) | 2015 |
| 26120368 | Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. | Alzheimers Res Ther | 2015 |
| 26120369 | Alzheimer's disease progression by geographical region in a clinical trial setting. | Alzheimers Res Ther | 2015 |